Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABIMMUNE
2024-514920-18-00Phase 2Completed
- Sponsor
- Gustave Roussy
- Start
- Jul 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tiragolumab in head and neck squamous cell carcinoma (HNSCC), Pulmonary squamous cell carcinoma, Esophageal Squamous Cell Carcinoma (ESCC) and 4 more, sponsored by Gustave Roussy. Started Jul 2024; status: completed.
02
Drugs
durvalumabtiragolumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)Pulmonary squamous cell carcinomaEsophageal Squamous Cell Carcinoma (ESCC)cervical squamous cell carcinoma (CSCC)vaginal squamous cell carcinoma (SCCV)
Beyond the preview
Go deeper on 2024-514920-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514920-18-00.